GLP-1s have been a breakthrough for obesity and diabetes. A 2022 study examined data from trials of GLP-1s in nearly 16,000 patients with diabetes, and showed that the drugs were associated with a 53% ...
Alzheimer’s isn’t just one problem—it’s a tangled mix of biology, aging, and overall health. That’s why drugs targeting a single factor have fallen short, even as new treatments show modest benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results